Construction of a disulfide-stabilized diabody against fibroblast growth factor-2 and the inhibition activity in targeting breast cancer

被引:20
|
作者
Cai, Yaxiong [1 ]
Zhang, Jinxia [1 ]
Lao, Xuejun [2 ]
Jiang, Haowu [1 ]
Yu, Yunfei [1 ]
Deng, Yanrui [1 ]
Zhong, Jiangchuan [1 ]
Liang, Yiye [1 ]
Xiong, Likuan [3 ]
Deng, Ning [1 ,3 ]
机构
[1] Jinan Univ, Biomed Translat Inst, Guangdong Prov Key Lab Mol Immunol & Antibody Eng, 601 West Huangpu Ave, Guangzhou 510632, Guangdong, Peoples R China
[2] Jinan Univ, Sch Clin 1, Dept Gastrointestinal Surg, Guangzhou, Guangdong, Peoples R China
[3] Jinan Univ, Affiliated Hosp, Shenzhen Key Lab Birth Defects Baoan Maternal & C, Shenzhen, Peoples R China
来源
CANCER SCIENCE | 2016年 / 107卷 / 08期
关键词
Breast cancer; ds-Diabody; FGF-2; Pichia pastoris; tumor angiogenesis; MONOCLONAL-ANTIBODIES; TUMOR ANGIOGENESIS; IN-VIVO; BIOLOGICAL-ACTIVITY; FACTOR RECEPTORS; PICHIA-PASTORIS; FV FRAGMENTS; VEGF-A; PROTEIN; FGF-2;
D O I
10.1111/cas.12981
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Fibroblast growth factor-2 (FGF-2) is one of the most important angiogenic factors to promote tumor growth, progression and metastasis. Neutralizing antibodies against FGF-2 may suppress the growth of tumor cells by blocking the FGF-2 signaling pathway. In this study, a disulfide-stabilized diabody (ds-Diabody) that specifically targets FGF-2 was designed. Compared to its parent antibody, the introduction of disulphide bonds in the diabody could significantly increase the stability of ds-Diabody and maintain its antigen binding activity. The ds-Diabody against FGF-2 could effectively inhibit the tube formation and migration of vascular endothelial cells and block the proliferation and invasion of human breast cancer cells. In the mouse model of breast cancer xenograft tumors, the ds-Diabody against FGF-2 could significantly inhibit the growth of tumor cells. Moreover, the densities of microvessels stained with CD31 and lymphatic vessels stained with LYVE1 in tumors showed a significant decrease following treatment with the ds-Diabody against FGF-2. Our data indicated that the ds-Diabody against FGF-2 could inhibit tumor angiogenesis, lymphangiogenesis and tumor growth.
引用
收藏
页码:1141 / 1150
页数:10
相关论文
共 50 条
  • [31] Fibroblast Growth Factor-2 Antagonist and Antiangiogenic Activity of Long-Pentraxin 3-Derived Synthetic Peptides
    Leali, D.
    Alessi, P.
    Coltrini, D.
    Rusnati, M.
    Zetta, L.
    Presta, M.
    CURRENT PHARMACEUTICAL DESIGN, 2009, 15 (30) : 3577 - 3589
  • [32] Osteostatin improves the osteogenic activity of fibroblast growth factor-2 immobilized in Si-doped hydroxyapatite in osteoblastic cells
    Lozano, Daniel
    Feito, Maria Jose
    Portal-Nunez, Sergio
    Lozano, Rosa Maria
    Matesanz, Maria Concepcion
    Serrano, Maria Concepcion
    Vallet-Regi, Maria
    Portoles, Maria Teresa
    Esbrit, Pedro
    ACTA BIOMATERIALIA, 2012, 8 (07) : 2770 - 2777
  • [33] Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer
    Awada, Gil
    Gombos, Andrea
    Aftimos, Philippe
    Awada, Ahmad
    EXPERT OPINION ON EMERGING DRUGS, 2016, 21 (01) : 91 - 101
  • [34] BRAF kinase inhibitor exerts anti-tumor activity against breast cancer cells via inhibition of FGFR2
    Zhang, Zong Xin
    Jin, Wen Jun
    Yang, Sheng
    Ji, Cun Li
    AMERICAN JOURNAL OF CANCER RESEARCH, 2016, 6 (05): : 1040 - +
  • [35] Exploiting Surface Plasmon Resonance (SPR) Technology for the Identification of Fibroblast Growth Factor-2 (FGF2) Antagonists Endowed with Antiangiogenic Activity
    Rusnati, Marco
    Bugatti, Antonella
    Mitola, Stefania
    Leali, Daria
    Bergese, Paolo
    Depero, Laura E.
    Presta, Marco
    SENSORS, 2009, 9 (08) : 6471 - 6503
  • [36] Fibroblast growth factor-2 has opposite effects on human breast cancer MCF-7 cell growth depending on the activation level of the mitogen-activated protein kinase pathway
    Liu, JF
    Issad, T
    Chevet, E
    Ledoux, D
    Courty, J
    Caruelle, JP
    Barritault, D
    Crepin, M
    Bertin, B
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 1998, 258 (01): : 271 - 276
  • [37] Regulation of physicochemical properties, osteogenesis activity, and fibroblast growth factor-2 release ability of β-tricalcium phosphate for bone cement by calcium silicate
    Su, Ching-Chuan
    Kao, Chia-Tze
    Hung, Chi-Jr
    Chen, Yi-Jyun
    Huang, Tsui-Hsien
    Shie, Ming-You
    MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS, 2014, 37 : 156 - 163
  • [38] Fibroblast growth factor 8 increases breast cancer cell growth by promoting cell cycle progression and by protecting against cell death
    Nilsson, Emeli M.
    Brokken, Leon J. S.
    Harkonen, Pirkko L.
    EXPERIMENTAL CELL RESEARCH, 2010, 316 (05) : 800 - 812
  • [39] The antiapoptotic effect of fibroblast growth factor-2 is mediated through nuclear factor-κB activation induced via interaction between Akt and IκB kinase-β in breast cancer cells
    Vandermoere, F
    El Yazidi-Belkoura, I
    Adriaenssens, E
    Lemoine, J
    Hondermarck, H
    ONCOGENE, 2005, 24 (35) : 5482 - 5491
  • [40] Fibroblast growth factor 2 expression on lymph node metastasis in early-stage breast cancer
    Kartini, Diani
    Panigoro, Sonar Soni
    Alam, Islam Akbar
    Dien, Alban Willian
    Soemarko, Dewi Sumaryani
    Hellyanti, Tantri
    Wardhana, Jessica Dewati
    Marcevianto, Kevin Varian
    BALI MEDICAL JOURNAL, 2023, 12 (01) : 621 - 625